Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis
Pain Medicine · 01.03.2023 · 24 (3) · 341-350
DOI: 10.1093/pm/pnac136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Medicine, online erschienen am 14.09.2022. Verfasst von Lynn R Webster und 4 weiteren Autor:innen. Beteiligte Einrichtung: PRA Health Sciences, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Chronic Pain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Salix Pharmaceuticals, Bausch Health US, Lantheus Holdings, Inc..
Abstract (Originalsprache)
Objective
Preclinical and clinical studies suggest that activation of the µ-opioid receptor may reduce overall survival and increase the risk for all-cause mortality in patients with cancer and noncancer pain. Methylnaltrexone, a selective, peripherally acting µ-opioid receptor antagonist, has demonstrated efficacy for the treatment of opioid-induced constipation. This retrospective analysis of 12 randomized, double-blind, placebo-controlled studies of methylnaltrexone evaluated the treatment of opioid-induced bowel disorders in patients with advanced illness or noncancer pain.
Methods
The risk of all-cause mortality within 30 days after the last dose of study medication during the double-blind phase was compared between methylnaltrexone and placebo groups. The data were further stratified by cancer vs noncancer, age, gender, and acute vs chronic diagnoses.
Results
Pooled data included 2,526 methylnaltrexone-treated patients of which 33 died, and 1,192 placebo-treated patients of which 35 died. The mortality rate was 17.8 deaths/100 person-years of exposure in the methylnaltrexone group and 49.5 deaths/100 person-years of exposure for the placebo group. The all-cause mortality risk was significantly lower among patients receiving methylnaltrexone compared with placebo (hazard ratio: 0.399, 95% confidence interval: 0.25, 0.64; P = .0002), corresponding to a 60% risk reduction. Significant risk reductions were observed for those receiving methylnaltrexone who had cancer or chronic diagnoses. Methylnaltrexone-treated patients had a significantly reduced mortality risk compared with placebo regardless of age or gender.
Conclusions
Methylnaltrexone reduced all-cause mortality vs placebo treatment across multiple trials, suggesting methylnaltrexone may confer survival benefits in patients with opioid-induced bowel disorders taking opioids for cancer-related or chronic noncancer pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PRA Health Sciences, Salt Lake City, Utah, USA.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Bausch Health US, LLC, Bridgewater, New Jersey, USA.
- Progenics Pharmaceuticals, Inc., a subsidiary of Lantheus Holdings Inc., North Billerica, Massachusetts, USA.
- University of California Riverside, School of Medicine, Riverside, California, USA.
- Salix Pharmaceuticals, a Division of Bausch Health US, LLC, Bridgewater, New Jersey, USA.
ORCID-Profile: Lynn R Webster
Förderung
- Salix Pharmaceuticals
- Bausch Health US
- Lantheus Holdings, Inc.
Zitieren
APA
Webster, L. R., Brenner, D., Israel, R. J., Stambler, N., & Slatkin, N. E. (2023). Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis. Pain Medicine, 24(3), 341-350. https://doi.org/10.1093/pm/pnac136
Vancouver
Webster LR, Brenner D, Israel RJ, Stambler N, Slatkin NE. Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis. Pain Medicine. 2023;24(3):341-350. doi:10.1093/pm/pnac136
BibTeX
@article{Webster2023,
author = {Webster, Lynn R and Brenner, Darren and Israel, Robert J and Stambler, Nancy and Slatkin, Neal E},
title = {Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis},
journal = {Pain Medicine},
year = {2023},
volume = {24},
number = {3},
pages = {341--350},
doi = {10.1093/pm/pnac136}
}
EUVIMED